Jennifer A. Fox - Sep 12, 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
Chief Business Officer and Chief Financial Officer
Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact
Stock symbol
ZBIO
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
4
Date filed
9/16/2024, 08:48 PM
Previous filing
Sep 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Stock Option (Right to Buy) Award $0 +155K $0.00 155K Sep 12, 2024 Common Stock 155K $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service.

Remarks:

Chief Business Officer and Chief Financial Officer